Literature DB >> 6572554

Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts.

D K Kalwinsky, A T Look, J Ducore, A Fridland.   

Abstract

Serial studies of human leukemic lymphoblasts (CCRF-CEM line) cultured with 0.25 to 2.5 microM VP-16-213 for 0 to 6 hr indicated that the mechanism of cytotoxicity of this compound involves a primary effect on DNA. The most striking early change shown by flow cytometry in VP-16-213-treated cells was a delay in S-phase transit before arrest of cells in G2. Coinciding with this S-phase delay was a selective inhibition of thymidine incorporation into DNA as well as concentration-dependent scission of DNA strands. Using alkaline elution methods, we were able to detect DNA breakage at concentrations of VP-16-213 well below the level required to demonstrate kinetic effects or inhibition of DNA synthesis. These data suggest that DNA strand scission is the initial event in the sequence of kinetic and biosynthetic changes leading to growth inhibition and death of VP-16-213-treated cells. Inhibition of replicon initiation due to strand scission is a plausible explanation for the cytotoxic action of this podophyllotoxin derivative.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6572554

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes.

Authors:  W K Kaufmann; J C Boyer; L L Estabrooks; S J Wilson
Journal:  Mol Cell Biol       Date:  1991-07       Impact factor: 4.272

2.  Inhibitors of DNA topoisomerase II prevent chromatid separation in mammalian cells but do not prevent exit from mitosis.

Authors:  C S Downes; A M Mullinger; R T Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

Review 3.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

Review 4.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

5.  Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells.

Authors:  D Roberts; T Lee; E Parganas; L Wiggins; J Yalowich; R Ashmun
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Antibacterial effect of etoposide in vitro.

Authors:  W Calame; R van der Waals; N Douwes-Idema; H Mattie; R van Furth
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

7.  A mitotic topoisomerase II checkpoint in budding yeast is required for genome stability but acts independently of Pds1/securin.

Authors:  Catherine A Andrews; Amit C Vas; Brian Meier; Juan F Giménez-Abián; Laura A Díaz-Martínez; Julie Green; Stacy L Erickson; Kristyn E Vanderwaal; Wei-Shan Hsu; Duncan J Clarke
Journal:  Genes Dev       Date:  2006-05-01       Impact factor: 11.361

Review 8.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

9.  Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks.

Authors:  Michelle Sabourin; John L Nitiss; Karin C Nitiss; Kazuo Tatebayashi; Hideo Ikeda; Neil Osheroff
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

Review 10.  Pharmacokinetic optimisation of treatment with oral etoposide.

Authors:  Giuseppe Toffoli; Giuseppe Corona; Barbara Basso; Mauro Boiocchi
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.